Assembly Biosciences, Inc. (ASMB) Fair Value 2026

ASMB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, Assembly Biosciences, Inc. (ASMB) trades at $34.07, versus a $4.69 median fair value across its 2 active models — 86.2% below the current price. QOC: 6.3/10. Value Trap Risk: 36/100 (LOW). 2/13 models active.

Key Facts

Ticker
ASMB
Price
$34.07
Quality Score
6.3/10
Value Trap Risk
36/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Assembly Biosciences, Inc. (ASMB) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Assembly Biosciences, Inc. (ASMB) appears overvalued as of : the median of 2 independent fair value estimates is $4.69, 86.2% below the current price of $34.07. Estimates range from $1.68 to $7.71. ASMB scores 6.3/10 on fundamental quality and 36/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ASMB’s -86.2% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Assembly Biosciences, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ASMB?

2 Intrinsic Value Models vs. Current Price ($34.07)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $1.68 -95.1%
Relative · Low Conviction
 $7.71 -77.4%

All Models Active

All 2 models are displayed above.

What Is Assembly Biosciences, Inc. (ASMB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Assembly Biosciences, Inc.'s intrinsic value is estimated at $4.69, suggesting the stock is overvalued at its current price of $34.07. With 2 out of 2 models flagging downside (-86.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About ASMB?

2 of 13 models are currently active for ASMB. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for ASMB is $4.69 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ASMB Rank in Biotechnology?

Among 625 Biotechnology stocks, ASMB ranks #110 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Assembly Biosciences, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ASMB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ASMB a Value Trap?

CirclFi's Value Trap algorithm assigns ASMB a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Assembly Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Assembly Biosciences, Inc.'s fundamental quality profile registers 6.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+17.7% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ASMB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ASMB's 2 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Assembly Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CTMXCytomX Therapeutics, Inc.QOC 6.3QUREuniQure N.V.QOC 6.3STROSutro Biopharma, Inc.QOC 6.3VTGNVistagen Therapeutics, Inc.QOC 6.3TCRXTScan Therapeutics, Inc.QOC 6.4SEPNSepterna, Inc.QOC 6.3MLECMoolec Science SAQOC 5.2MNPRMonopar Therapeutics Inc.QOC 4.6ZVSAZyVersa Therapeutics, Inc.QOC 3.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CTMX · QURE · STRO · VTGN · TCRX · SEPN · MLEC · MNPR · ZVSA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ASMB?

5 companies across all industries closest to ASMB’s Quality of Company score of 6.3/10.

VPRBVPR Brands, LPQOC 6.3CREXCreative Realities, Inc.QOC 6.3PETVPetVivo Holdings, Inc.QOC 6.3ADMQADM Endeavors, Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VPRB · CREX · PETV · ADMQ · NVDA

Where Does ASMB Sit in CirclFi's Biotechnology Rankings?

ASMB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Assembly Biosciences, Inc.’s Valuation?

What is Assembly Biosciences, Inc.'s intrinsic value in 2026?

CirclFi puts Assembly Biosciences, Inc. (ASMB)'s intrinsic value at $4.69 — the median of 2 independent model estimates as of 2026-08-28, ranging from $1.68 to $7.71. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ASMB overvalued or undervalued right now?

At $34.07, 0 of 2 active models suggest ASMB may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $4.69, 86.2% below the current price of $34.07 — a consensus view that ASMB is overvalued. The assessment depends on which methodology best fits Assembly Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for ASMB?

Assembly Biosciences, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ASMB?

CirclFi analyzes ASMB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ASMB a value trap in 2026?

Assembly Biosciences, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Assembly Biosciences, Inc. (ASMB) has a median fair value of $4.69 — 86.2% below the current price of $34.07 — as of 2026-08-28.” Source: circlfi.com/stock/ASMB/ · Methodology
Primary sources for this ASMB valuation
  • Financial statements: Assembly Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001426800) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ASMB as of ; valuations recomputed .